trihexyphenidyl has been researched along with Marfan Syndrome in 2 studies
Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.
Marfan Syndrome: An autosomal dominant disorder of CONNECTIVE TISSUE with abnormal features in the heart, the eye, and the skeleton. Cardiovascular manifestations include MITRAL VALVE PROLAPSE, dilation of the AORTA, and aortic dissection. Other features include lens displacement (ectopia lentis), disproportioned long limbs and enlarged DURA MATER (dural ectasia). Marfan syndrome (type 1) is associated with mutations in the gene encoding FIBRILLIN-1 (FBN1), a major element of extracellular microfibrils of connective tissue. Mutations in the gene encoding TYPE II TGF-BETA RECEPTOR (TGFBR2) are associated with Marfan syndrome type 2.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rao, NP | 1 |
| Loganathan, S | 1 |
| Prakash, O | 1 |
| Varghese, M | 1 |
| Blackburn, JS | 1 |
| Cirillo, ML | 1 |
2 other studies available for trihexyphenidyl and Marfan Syndrome
| Article | Year |
|---|---|
Use of electroconvulsive therapy for schizophrenia with comorbid Marfan syndrome.
Topics: Adult; Antipsychotic Agents; Catatonia; Electroconvulsive Therapy; Female; Humans; Marfan Syndrome; | 2009 |
Clinical reasoning: A 13-year-old boy presenting with dystonia, myoclonus, and anxiety.
Topics: Adolescent; Anti-Dyskinesia Agents; Anxiety; Diagnosis, Differential; Dystonia; Genetic Testing; Han | 2012 |